4 MENORAT HAMAOR ST., TEL AVIV, L3
Announces the Appointment of Dan Dearen to its Board of Directors
Amended material disclosure
Reports Second Quarter 2025 Financial Results
Announces the Appointment of Raymond W. Cohen to its Board of Directors
Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
Investor Presentation
Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
Changes in Board, Management or Compensation, Reg. FD
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership